![](/images/graphics-bg.png)
Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease
Joint Authors
Fujiya, Mikihiro
Sakatani, Aki
Ito, Takahiro
Inaba, Yuhei
Ueno, Nobuhiro
Kashima, Shin
Tominaga, Motoya
Moriichi, Kentaro
Okamoto, Kotaro
Tanabe, Hiroki
Ohtake, Takaaki
Furukawa, Hiroyuki
Ashida, Toshifumi
Ikuta, Katsuya
Kohgo, Yutaka
Kono, Toru
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-11-26
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background/Aims.
While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn’s disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate.
We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis.
Methods.
The clinical records of 104 CD patients were retrospectively investigated.
The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments.
Results.
The 50% nonoperative interval in the 104 CD patients was 107 months.
The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate.
A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery.
Conclusions.
This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery.
The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.
American Psychological Association (APA)
Sakatani, Aki& Fujiya, Mikihiro& Ito, Takahiro& Inaba, Yuhei& Ueno, Nobuhiro& Kashima, Shin…[et al.]. 2013. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International،Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
Modern Language Association (MLA)
Sakatani, Aki…[et al.]. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International No. 2013 (2013), pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
American Medical Association (AMA)
Sakatani, Aki& Fujiya, Mikihiro& Ito, Takahiro& Inaba, Yuhei& Ueno, Nobuhiro& Kashima, Shin…[et al.]. Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1031052
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1031052